PL354980A1 - Use dexrazoxane for treating psoriasis - Google Patents

Use dexrazoxane for treating psoriasis

Info

Publication number
PL354980A1
PL354980A1 PL00354980A PL35498000A PL354980A1 PL 354980 A1 PL354980 A1 PL 354980A1 PL 00354980 A PL00354980 A PL 00354980A PL 35498000 A PL35498000 A PL 35498000A PL 354980 A1 PL354980 A1 PL 354980A1
Authority
PL
Poland
Prior art keywords
dexrazoxane
treating psoriasis
psoriasis
treating
use dexrazoxane
Prior art date
Application number
PL00354980A
Other languages
English (en)
Polish (pl)
Inventor
Iervant Zarmanian
Jadranka Rogan-Grgas
Original Assignee
Cyathus Exquirere Pharmaforschungs Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cyathus Exquirere Pharmaforschungs Gmbh filed Critical Cyathus Exquirere Pharmaforschungs Gmbh
Publication of PL354980A1 publication Critical patent/PL354980A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
PL00354980A 1999-09-10 2000-09-08 Use dexrazoxane for treating psoriasis PL354980A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AT155899 1999-09-10
US18380600P 2000-02-22 2000-02-22
PCT/EP2000/008879 WO2001019358A2 (en) 1999-09-10 2000-09-08 Use dexrazoxane for treating psoriasis

Publications (1)

Publication Number Publication Date
PL354980A1 true PL354980A1 (en) 2004-03-22

Family

ID=25596169

Family Applications (1)

Application Number Title Priority Date Filing Date
PL00354980A PL354980A1 (en) 1999-09-10 2000-09-08 Use dexrazoxane for treating psoriasis

Country Status (16)

Country Link
EP (1) EP1214073A2 (hu)
KR (1) KR20020035131A (hu)
CN (1) CN1378451A (hu)
AU (1) AU7286500A (hu)
BG (1) BG106428A (hu)
BR (1) BR0013921A (hu)
CA (1) CA2384685A1 (hu)
CZ (1) CZ2002729A3 (hu)
EE (1) EE04871B1 (hu)
HR (1) HRPK20020201B1 (hu)
HU (1) HUP0202791A3 (hu)
MX (1) MXPA02002486A (hu)
PL (1) PL354980A1 (hu)
RU (1) RU2002106874A (hu)
SK (1) SK2802002A3 (hu)
WO (1) WO2001019358A2 (hu)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021053523A1 (en) * 2019-09-18 2021-03-25 Tryp Therapeutics Compositions and methods to improve the therapeutic benefit of bis-dioxopiperazines
WO2023182298A1 (ja) 2022-03-22 2023-09-28 国立大学法人京都大学 脆弱ｘ症候群の治療または予防薬

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1234935A (en) * 1967-07-03 1971-06-09 Nat Res Dev Piperazine derivatives
US3941790A (en) * 1967-07-03 1976-03-02 National Research Development Corporation Bis diketopiperazines
US4963679A (en) * 1988-02-17 1990-10-16 Erbamont, Inc. Process for preparing bis (3,5-dioxopiperazinyl) alkanes or alkenes
KR960703597A (ko) * 1993-07-23 1996-08-31 데이비드 엘 토메이 아폽토시스 및 관련 상태의 치료방법(methods of treating apoptosis and associated conditions)

Also Published As

Publication number Publication date
HRP20020201A2 (en) 2003-06-30
HRPK20020201B1 (en) 2004-08-31
WO2001019358A2 (en) 2001-03-22
AU7286500A (en) 2001-04-17
KR20020035131A (ko) 2002-05-09
HUP0202791A3 (en) 2003-02-28
RU2002106874A (ru) 2003-11-20
WO2001019358A3 (en) 2001-10-04
EP1214073A2 (en) 2002-06-19
EE04871B1 (et) 2007-08-15
MXPA02002486A (es) 2004-09-10
SK2802002A3 (en) 2003-02-04
EE200200128A (et) 2003-04-15
CZ2002729A3 (cs) 2002-07-17
HUP0202791A2 (hu) 2003-01-28
BG106428A (en) 2003-04-30
BR0013921A (pt) 2002-05-14
CN1378451A (zh) 2002-11-06
CA2384685A1 (en) 2001-03-22

Similar Documents

Publication Publication Date Title
ZA200107291B (en) Use of xenon for treating neurointoxications.
GB2357761B (en) Compounds
GB2367248B (en) Applicator for reflexotherapy
GB0030757D0 (en) Equi-pressure geosteering
GB9900150D0 (en) Treatment for fabrics
GB9925136D0 (en) Novel treatment
EG24462A (en) Compounds for treating fundic disaccomodation
IL144186A0 (en) Novel treatment
GB9901838D0 (en) Slurry treatment
GB9902399D0 (en) Compounds
GB9900151D0 (en) Treatment for fabrics
PL354980A1 (en) Use dexrazoxane for treating psoriasis
HK1043938A1 (en) Composition for the treatment of psoriasis
GB9906993D0 (en) Psoriasis
GB9926635D0 (en) Bed
GB9919904D0 (en) Dressing
GB9908993D0 (en) Treatment
GB9912313D0 (en) Arthritis treatment
GB9900149D0 (en) Treatment for fabrics
GB9923111D0 (en) Effluent treatment
TW413384U (en) Transformer
GB9902226D0 (en) Waste treatment
GB9911902D0 (en) Waste treatment
GB9920787D0 (en) Novel treatment
GB9916655D0 (en) Novel treatment

Legal Events

Date Code Title Description
REFS Decisions on refusal to grant patents (taken after the publication of the particulars of the applications)